

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28865 A2

(51) International Patent Classification⁷: **C07D 498/14**,
A61K 31/437, A61P 9/00, 15/10, C07D 513/14, 471/14,
515/14 // (C07D 498/14, 263:00, 221:00, 209:00) (C07D
513/14, 277:00, 221:00, 209:00) (C07D 471/14, 235:00,
221:00, 209:00) (C07D 471/14, 221:00, 209:00, 209:00)
(C07D 515/14, 291:00, 221:00, 209:00)

de Recherche Glaxo Smith Kline Courtaboeuf Z.A. de
Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis
(FR). **SCHULTZE, Lisa, M.** [US/US]; 16110 N.E. 175th
Street, Woodinville, WA 98072 (US).

(21) International Application Number: PCT/US01/42175

(74) Agent: **NAPOLI, James, J.**; Marshall, Gerstein & Borun,
6300 Sears Tower, 233 South Wacker Drive, Chicago, IL
60606 (US).

(22) International Filing Date:
17 September 2001 (17.09.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/237,734 3 October 2000 (03.10.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant (*for all designated States except US*): **LILLY
ICOS LLC** [US/US]; 1209 Orange Street, Wilmington, DE
19801 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **ORME, Mark,
W.** [US/US]; 4235 Francis Avenue #203, Seattle, WA
98103 (US). **SAWYER, Jason, Scott** [US/US]; 5718
North Winthrop Avenue, Indianapolis, IN 46200 (US).
DAUGAN, Alain, Claude-Marie [FR/FR]; Centre de
Recherche Glaxo Smith Kline Courtaboeuf Z.A. de
Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis
(FR). **GOSIMINI, Romain, Luc, Marie** [FR/FR]; Centre

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: Compounds of the general structural formula and use of
the compounds and salts and solvates thereof, as therapeutic agents.

- 1 -


CHEMICAL COMPOUNDS

FIELD AND BACKGROUND OF THE INVENTION

5 This invention relates to a series of compounds, to methods of preparing the compounds, to pharmaceutical compositions containing the compounds, and to their use as therapeutic agents. In particular, the invention relates to compounds
 10 that are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial,
 15 including the treatment of cardiovascular disorders and erectile dysfunction.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides compounds of formula (I)




(I)

30 wherein R^0 , independently, is selected from the group consisting of halo, C_{1-6} alkyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{3-8} cycloalkylQ, $C(=O)R^b$, $OC(=O)R^b$, $C(=O)OR^b$, C_{1-4} alkylene NR^bR^c ,

- 2 -

C_{1-4} alkyleneHet, C_{1-4} alkyleneC(=O)OR^b, C(=O)NR^bSO₂R^d,
 C(=O) C_{1-4} alkyleneHet, C(=O)NR^bR^c, C(=O)NR^bR^d, C(=O)NR^b-
 C_{1-4} alkyleneOR^c, C(=O)NR^b C_{1-4} alkyleneHet, OR^b, OC₁₋₄-
 alkyleneC(=O)OR^b, OC₁₋₄alkyleneNR^bR^c, OC₁₋₄alkyleneHet,
 5 OC₁₋₄alkyleneOR^b, OC₁₋₄alkyleneNR^bC(=O)OR^c, NR^bR^c, NR^b-
 C_{1-4} alkyleneNR^bR^c, NR^bC(=O)R^c, NR^bC(=O)NR^bR^c, N(SO₂ C_{1-4} -
 alkyl)₂, NR^b(SO₂ C_{1-4} alkyl), nitro, trifluoromethyl,
 trifluoromethoxy, cyano, SO₂NR^bR^c, SO₂R^b, SOR^b, SR^b,
 and OSO₂CF₃;


10 R¹ is selected from the group consisting of
 optionally substituted aryl, optionally substituted
 heteroaryl, an optionally substituted C₃₋₈cycloalkyl
 ring, an optionally substituted C₃₋₈heterocycloalkyl
 ring, an optionally substituted bicyclic ring




20 wherein the fused ring A is a 5- or 6-membered ring,
 saturated or partially or fully unsaturated, and
 comprises carbon atoms and optionally one to three
 heteroatoms selected from oxygen, sulfur, and nitro-
 25 gen, hydrogen, C₁₋₆alkyl, arylC₁₋₃alkyl, C₁₋₃alkenyl-
 aryl, haloC₁₋₆alkyl, C₁₋₄alkyleneC(=O)OR^b, C₁₋₄alkylene-
 C(=O)NR^bR^c, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₈hetero-
 cycloalkenyl, C₁₋₄alkyleneHet, C₁₋₄alkyleneQR^b, C₂₋₆-
 alkenyleneQR^b, C₁₋₄alkyleneQC₁₋₄alkyleneQR^b,

30


- 3 -



5




10



15

and a spiro substituent having the structure

20



25

R^2 and R^4 , independently, are selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, C_{1-3} alkyleneHet, C_{3-8} cycloalkyl, and C_{3-8} heterocycloalkyl;

30

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocyclo-

- 4 -

alkyl, C₂₋₆alkenyl, C₁₋₃alkylenearyl, arylC₁₋₃alkyl, C(=O)R^b, aryl, heteroaryl, C(=O)R^b, C(=O)NR^bR^c, C(=O)NR^bR^d, C(=S)NR^bR^c, C(=S)NR^bR^d, SO₂R^b, SO₂NR^bR^c, S(=O)R^b, S(=O)NR^bR^c, C(=O)NR^bC₁₋₄alkyleneOR^b, C(=O)NR^bC₁₋₄alkyleneHet, C(=O)C₁₋₄alkylenearyl, C(=O)C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl substituted with one or more of SO₂NR^bR^c, NR^bR^c, C(=O)OR^b, NR^bSO₂CF₃, CN, NO₂, C(=O)R^b, OR^b, C₁₋₄alkyleneNR^bR^c, and OC₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=O)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneC(=O)NR^bR^c, C₁₋₄alkyleneOR^b, C₁₋₄alkyleneNR^bC(=O)R^b, C₁₋₄alkyleneOC₁₋₄alkyleneOR^b, C₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneC(=O)OR^b, and C₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^b;

X and Y, independently, are selected from the group consisting of C(=O), SO, SO₂, C(=S), C(R^a)₂, and C=C(R^a)₂;

Z is O, X, or C(R^a)₂, or Z is NR^d when X or Y is SO, SO₂, C(=S), C(R^a)₂ or C=C(R^a)₂;

R^a, independently, is selected from the group consisting of hydrogen, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, aryl, heteroaryl, arylC₁₋₃alkyl, C₁₋₃alkylenearyl, C(=O)OR^b, C(=O)NR^bR^d, C₁₋₄alkyleneNR^bR^c, halo, NO₂, CF₃, CF₃O, OR^b, OC(=O)R^b, OC₁₋₄alkyleneC(=O)OR^b, C₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^b, C(=O)NR^bSO₂R^d, C(=O)C₁₋₄alkyleneHet, C₂₋₆alkenyleneNR^bR^c, C(=O)NR^aC₁₋₄alkyleneOR^c, C(=O)NR^bC₁₋₄alkyleneHet, OC₂₋₄alkyleneNR^bR^c, OC₁₋₄alkyleneCH(OR^b)CH₂NR^bR^c, OC₂₋₄alkyleneOR^b, OC₂₋₄alkyleneNR^bC(=O)OR^c, NR^bR^c, NR^bC₁₋₄alkyleneNR^bR^c, NR^bC(=O)R^c, NR^bC(=O)NR^bR^c, N(SO₂C₁₋₄alkyl)₂, NR^b(SO₂C₁₋₄alkyl), SO₂NR^bR^c, OSO₂trifluoro-

- 5 -

methyl, $C(=O)R^b$, C_{1-3} alkylene OR^b , CN, and C_{1-6} alkylene $C(=O)OR^b$;

5 R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

R^c is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-3} alkylene $N(R^b)_2$, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and heteroaryl;

10 R^d is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylene $N(R^a)_2$, C_{1-6} alkylenearyl, C_{1-6} alkyleneHet, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneHet, C_{1-3} alkyleneheteroaryl, C_{1-6} alkylene $C(=O)OR^a$, and C_{1-3} alkylene C_{3-8} heterocycloalkyl;

or R^b and R^d are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

20 R^e is null or is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and C_{1-3} alkyleneheteroaryl;

25 Q is O, S, or NR^b ;

B is O, S, or NR^e ;

C is O, S, or NR^b ;

D is CR^b or N;

E is CR^b , $C(R^a)_2$, or NR^e ;

30 Het represents a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and

- 6 -

sulfur, and optionally substituted with C₁₋₄alkyl or C(=O)OR^b;

q is 0, 1, 2, 3, or 4; and

pharmaceutically acceptable salts and
5 hydrates thereof.

As used herein, the term "alkyl" includes straight chained and branched hydrocarbon groups containing the indicated number of carbon atoms, typically methyl, ethyl, and straight chain and
10 branched propyl and butyl groups. The hydrocarbon group can contain up to 16 carbon atoms. The term "alkyl" includes "bridged alkyl," i.e., a C₆-C₁₆ bicyclic or polycyclic hydrocarbon group, for example, norbornyl, adamantyl, bicyclo[2.2.2]octyl,
15 bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, or decahydronaphthyl. The term "cycloalkyl" is defined as a cyclic C₃-C₈ hydrocarbon group, e.g., cyclopropyl, cyclobutyl, cyclohexyl, and cyclopentyl.

The terms "alkenyl" and "alkynyl" are
20 defined identically as "alkyl," except for containing a carbon-carbon double bond or carbon-carbon triple bond, respectively. "Cycloalkenyl" is defined similarly to cycloalkyl, except a carbon-carbon double bond is present in the ring.

25 The term "alkylene" refers to an alkyl group having a substituent. For example, the term "C₁₋₃alkylenearyl" refers to an alkyl group containing one to three carbon atoms, and substituted with an aryl group. The term "alkenylene" as used herein
30 is similarly defined, and contains the indicated number of carbon atoms and a carbon-carbon double bond, and includes straight chained and branched alkenylene groups, like ethylenylene.

- 7 -

The term "halo" or "halogen" is defined herein to include fluorine, bromine, chlorine, and iodine.

5 The term "haloalkyl" is defined herein as an alkyl group substituted with one or more halo substituents, either fluoro, chloro, bromo, iodo, or combinations thereof. Similarly, "halocycloalkyl" is defined as a cycloalkyl group having one or more halo substituents.

10 The term "aryl," alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl. Unless otherwise indicated, an "aryl" group can be unsubstituted or substituted, for example, with one or
15 more, and in particular one to three, halo, alkyl, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl. Exemplary aryl groups
20 include phenyl, naphthyl, tetrahydronaphthyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, and the like. The terms
25 "arylC₁₋₃alkyl" and "heteroarylC₁₋₃alkyl" are defined as an aryl or heteroaryl group having a C₁₋₃alkyl substituent.

30 The term "heteroaryl" is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy,

- 8 -

hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfanyl, and alkylsulfonyl. Examples of heteroaryl groups include thienyl, furyl, pyridyl, oxazolyl, quinolyl, isoquinolyl, indolyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl.

The term "Het" is defined as monocyclic, bicyclic, and tricyclic groups containing one or more heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. A "Het" group also can contain an oxo group (=O) attached to the ring. Nonlimiting examples of Het groups include 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, a pyrroline, 2H-pyran, 4H-pyran, morpholine, thiopholine, piperidine, 1,4-dithiane, and 1,4-dioxane.

The term "hydroxy" is defined as -OH.

The term "alkoxy" is defined as -OR, wherein R is alkyl.

The term "alkoxyalkyl" is defined as an alkyl group wherein a hydrogen has been replaced by an alkoxy group. The term "(alkylthio)alkyl" is defined similarly as alkoxyalkyl, except a sulfur atom, rather than an oxygen atom, is present.

The term "hydroxyalkyl" is defined as a hydroxy group appended to an alkyl group.

The term "amino" is defined as -NH₂, and the term "alkylamino" is defined as -NR₂, wherein at least one R is alkyl and the second R is alkyl or hydrogen.

The term "acylamino" is defined as RC(=O)N, wherein R is alkyl or aryl.

- 9 -

The term "alkylthio" is defined as -SR, wherein R is alkyl.

The term "alkylsulfinyl" is defined as R-SO₂, wherein R is alkyl.

5 The term "alkylsulfonyl" is defined as R-SO₃, wherein R is alkyl.

The term "nitro" is defined as -NO₂.

The term "trifluoromethyl" is defined as -CF₃.

10 The term "trifluoromethoxy" is defined as -OCF₃.


The term "spiro" as used herein refers to a group having two carbon atoms directly bonded to the carbon atom to which R¹ is attached.

15 The term "cyano" is defined as -CN.

In a preferred embodiment, R⁰ is selected from the group consisting of aryl, Het, OR^a, C(=O)-OR^a, C₁₋₄alkyleneNR^aR^b, OC(=O)R^a, C(=O)R^a, NR^aR^b, C₃₋₈-cycloalkyl, C₃₋₈cycloalkylQ, C(=O)NR^aR^b, and C(=O)-NR^aR^c, or two R⁰ groups are taken together with the carbon atoms to which they are attached to form a 5- or 6-membered ring, saturated or partially or fully saturated, optionally substituted and optionally containing one or two heteroatoms selected from oxygen, nitrogen, and sulfur.


25 In a preferred group of compounds of formula (I), R¹ is represented by

30



- 10 -

wherein the bicyclic ring can represent,
for example, naphthalene or indene, or a hetero-
cycle, such as benzoxazole, benzothiazole, benzi-
soxazole, benzimidazole, quinoline, indole, benzo-
5 thiophene, or benzofuran, or




10

wherein q is an integer 1 or 2, and G , independent-
ly, is $C(R^a)_2$, O , S , or NR^a . The bicyclic ring com-
prising the R^1 substituent typically is attached to
15 the rest of the molecule by a phenyl ring carbon
atom.

In another preferred group of compounds of
formula (I), R^1 is represented by an optionally sub-
stituted bicyclic ring


20




25

wherein q is 1 or 2, and G , independently, are $C(R^a)_2$
or O . Especially preferred R^1 substituents include


- 11 -



5




10



15

and



20


Within this particular group of compounds, nonlimiting examples of substituents for the bicyclic ring include halogen (e.g., chlorine), C₁₋₃alkyl (e.g., methyl, ethyl, or i-propyl), OR^a (e.g., methoxy, ethoxy, or hydroxy), CO₂R^a, halomethyl or halomethoxy (e.g., trifluoromethyl or trifluoromethoxy), cyano, nitro, and NR^aR^b.

25


In other preferred embodiments, R¹ is optionally substituted and selected from the group consisting of C₁₋₄alkyleneQR^a, C₁₋₄alkyleneQC₁₋₄alkyleneQR^a, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₁₋₆alkyl,

30


- 12 -




5



10




15




20

In a more preferred group of compounds of
 formula (I), R^1 is represented by




30

- 13 -



5




10


C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{1-6} alkyl, C_{1-4} alkyl-eneQR^a, and C_{1-4} alkyleneQC₁₋₄alkyleneQR^a. A preferred Q is oxygen.

15


Especially preferred R¹ substituents include



20




25




30

- 14 -




5



10


$-\text{CH}_2\text{OR}^a$, $-\text{CH}_2\text{OCH}_2\text{OR}^a$,

15



and

20



Within this particular group of compounds, preferred R^a substituents include hydrogen, C_{1-6} alkyl, and benzyl.

25


In a preferred embodiment, R^3 is selected from the group consisting of aryl, heteroaryl, OR^b , NR^bR^c , NR^bR^d , C_{1-4} alkyleneHet, C_{1-4} alkyleneheteroaryl, C_{1-4} alkylenearyl, C_{1-4} alkylene $\text{C}(=\text{O})\text{C}_{1-4}$ alkylenearyl, C_{1-4} alkylene $\text{C}(=\text{O})\text{OR}^b$, C_{1-4} alkylene $\text{C}(=\text{O})\text{NR}^b\text{R}^c$, C_{1-4} alkylene $\text{C}(=\text{O})\text{NR}^b\text{R}^d$, C_{1-4} alkylene $\text{C}(=\text{O})\text{Het}$, C_{1-4} alkylene NR^bR^c ,

30


- 15 -

C_{1-4} alkylene NR^bR^d , C_{1-4} alkylene $NR^bC(=O)R^b$, and C_{1-4} alkylene OC_{1-4} alkylene OR^b .

In more preferred embodiments, R^3 is selected from the group consisting of C_{1-4} alkyleneheteroaryl, wherein the heteroaryl group is selected from the group consisting of benzimidazole, a triazole, and imidazole; C_{1-4} alkyleneHet, wherein Het is selected from the group consisting of piperazine, morpholine, pyrrolidine, pyrrolidone, tetrahydrofuran, piperidine,



and




C_{1-4} alkylene C_6H_5 , optionally substituted with one to three groups selected from the group consisting of $C(=O)OR^b$, NR^bR^c , $NR^bSO_2CF_3$, $SO_2NR^bR^c$, CN , OR^b , $C(=O)R^b$, C_{1-4} alkylene NR^bR^c , nitro, OC_{1-4} alkylenearyl, and OC_{1-4} alkylene NR^bR^c ; C_{1-4} alkylene $C(=O)$ benzyl; C_{1-4} alkylene $C(=O)OR^b$; C_{1-4} alkylene $C(=O)NR^bR^c$; C_{1-4} alkylene $C(=O)NR^bR^d$; C_{1-4} alkyleneHet; NR^bR^c ; OH ; OC_{1-4} alkyl; C_6H_5 ; C_{1-4} alkylene NR^bR^c ; C_{1-4} alkylene OR^b ; C_{1-4} alkylene $NHC(=O)R^b$; and C_{1-4} alkylene OC_{1-4} alkylene OR^b .

- 16 -


In preferred embodiments, R^2 and R^4 , independently, are hydrogen, C_{1-6} alkyl, aryl, or hetero-aryl.

5 In especially preferred embodiments, R^0 is selected from the group consisting of halo, methyl, trifluoromethyl, and trifluoromethyl; R^1 is selected from the group consisting of

10




15



20


25




30

- 17 -


5



10




15




20

25



and


- 18 -




5

10 R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, $C(=O)NR^bR^d$, and C_{1-4} alkyleneHet; R^2 and R^4 are selected from the group consisting of hydrogen and C_{1-6} alkyl; and $-X-Z-Y-$ is selected from the group consisting of


15




20




25




30




- 19 -




5




10




15




20




25




30




- 20 -




5



10



15




wherein R^d is hydrogen, benzyl, or C_{1-6} alkyl.

20

An especially preferred subclass of compounds within the general scope of formula (I) is represented by compounds of formula (II)

25



30

(II)

Compounds of formula (I) can contain one or more asymmetric center, and, therefore, can exist

- 21 -

as stereoisomers. The present invention includes both mixtures and separate individual stereoisomers of the compounds of formula (I). Compounds of formula (I) also can exist in tautomeric forms, and the invention includes both mixtures and separate individual tautomers thereof.

Pharmaceutically acceptable salts of the compounds of formula (I) can be acid addition salts formed with pharmaceutically acceptable acids. Examples of suitable salts include, but are not limited to, the hydrochloride, hydrobromide, sulfate, bisulfate, phosphate, hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate salts. The compounds of the formula (I) also can provide pharmaceutically acceptable metal salts, in particular alkali metal salts and alkaline earth metal salts, with bases. Examples include the sodium, potassium, magnesium, and calcium salts.

Compounds of the present invention are potent and selective inhibitors of cGMP-specific PDE5. Thus, compounds of formula (I) are of interest for use in therapy, specifically for the treatment of a variety of conditions where selective inhibition of PDE5 is considered to be beneficial.

Phosphodiesterases (PDEs) catalyze the hydrolysis of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The PDEs have been classified into at least seven isoenzyme families and are present in many tissues (J.A. Beavo, *Physiol. Rev.*, 75, p. 725 (1995)).

- 22 -

PDE5 inhibition is a particularly attractive target. A potent and selective inhibitor of PDE5 provides vasodilating, relaxing, and diuretic effects, all of which are beneficial in the treatment of various disease states. Research in this area has led to several classes of inhibitors based on the cGMP basic structure (E. Sybertz et al., *Expert. Opin. Ther. Pat.*, 7, p. 631 (1997)).

The biochemical, physiological, and clinical effects of PDE5 inhibitors therefore suggest their utility in a variety of disease states in which modulation of smooth muscle, renal, hemostatic, inflammatory, and/or endocrine function is desirable. The compounds of formula (I), therefore, have utility in the treatment of a number of disorders, including stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, acute respiratory distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., postpercutaneous transluminal coronary or carotid angioplasty, or post-bypass surgery graft stenosis), peripheral vascular disease, vascular disorders, such as Raynaud's disease, thrombocytopenia, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, peptic ulcer, male erectile dysfunction, female sexual dysfunction, and diseases characterized by disorders of gut motility (e.g., irritable bowel syndrome).

An especially important use is the treatment of male erectile dysfunction, which is one form

- 23 -

of impotence and is a common medical problem. Impotence can be defined as a lack of power, in the male, to copulate, and can involve an inability to achieve penile erection or ejaculation, or both.

5 The incidence of erectile dysfunction increases with age, with about 50% of men over the age of 40 suffering from some degree of erectile dysfunction.

In addition, a further important use is the treatment of female arousal disorder. Female
10 arousal disorders are defined as a recurrent inability to attain or maintain an adequate lubrication/swelling response of sexual excitement until completion of sexual activity. The arousal response consists of vasocongestion in the pelvis, vaginal lubrication, and expansion and swelling of external
15 genitalia.

It is envisioned, therefore, that compounds of formula (I) are useful in the treatment of male erectile dysfunction and female arousal disorder. Thus, the present invention concerns the use
20 of compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic
25 treatment of erectile dysfunction in a male animal and arousal disorder in a female animal, including humans.

The term "treatment" includes preventing, lowering, stopping, or reversing the progression or
30 severity of the condition or symptoms being treated. As such, the term "treatment" includes both medical therapeutic and/or prophylactic administration, as appropriate.

- 24 -

It also is understood that "a compound of formula (I)," or a physiologically acceptable salt or solvate thereof, can be administered as the neat compound, or as a pharmaceutical composition containing either entity.

Although the compounds of the invention are envisioned primarily for the treatment of sexual dysfunction in humans, such as male erectile dysfunction and female arousal disorder, they also can be used for the treatment of other disease states.

A further aspect of the present invention, therefore, is providing a compound of formula (I) for use in the treatment of stable, unstable, and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, acute respiratory distress syndrome, acute and chronic renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g., post-PTCA or post-bypass graft stenosis), peripheral vascular disease, vascular disorders such as Raynaud's disease, thrombocythemia, inflammatory diseases, prophylaxis of myocardial infarction, prophylaxis of stroke, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, osteoporosis, preterm labor, benign prostatic hypertrophy, male and female erectile dysfunction, or diseases characterized by disorders of gut motility (e.g., IBS).

According to another aspect of the present invention, there is provided the use of a compound of formula (I) for the manufacture of a medicament for the treatment of the above-noted conditions and disorders.

- 25 -

In a further aspect, the present invention provides a method of treating the above-noted conditions and disorders in a human or nonhuman animal body which comprises administering to said body a therapeutically effective amount of a compound of formula (I).

Compounds of the invention can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, transurethral, nasal, topical, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration. Parenteral administration can be accomplished using a needle and syringe, or using a high pressure technique, like POWDERJECT™.

Oral administration of a compound of the invention is the preferred route. Oral administration is the most convenient and avoids the disadvantages associated with other routes of administration. For patients suffering from a swallowing disorder or from impairment of drug absorption after oral administration, the drug can be administered parenterally, e.g., sublingually or buccally.

Compounds and pharmaceutical compositions suitable for use in the present invention include those wherein the active ingredient is administered in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount" means an amount effective to prevent development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capabil-

- 26 -

ity of those skilled in the art, especially in light of the detailed disclosure provided herein.

A "therapeutically effective dose" refers to that amount of the compound that results in achieving the desired effect. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from such data can be used in formulating a dosage range for use in humans. The dosage of such compounds preferably lies within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized.

The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the therapeutic effects.

The amount of composition administered is dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.

- 27 -

Specifically, for administration to a human in the curative or prophylactic treatment of the conditions and disorders identified above, oral dosages of a compound of formula (I) generally are about 0.5 to about 1000 mg daily for an average adult patient (70 kg). Thus, for a typical adult patient, individual tablets or capsules contain 0.2 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal, or sublingual administration typically are 0.1 to 500 mg per single dose as required. In practice, the physician determines the actual dosing regimen which is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient. The above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this invention.

For human use, a compound of the formula (I) can be administered alone, but generally is administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of compounds of formula (I) into preparations which can be used pharmaceutically.

- 28 -

These pharmaceutical compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of a compound of the present invention is administered orally, the composition typically is in the form of a tablet, capsule, powder, solution, or elixir. When administered in tablet form, the composition can additionally contain a solid carrier, such as a gelatin or an adjuvant. The tablet, capsule, and powder contain about 5 to about 95% compound of the present invention, and preferably from about 25 to about 90% compound of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, or oils of animal or plant origin can be added. The liquid form of the composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols. When administered in liquid form, the composition contains about 0.5 to about 90% by weight of a compound of the present invention, and preferably about 1 to about 50% of a compound of the present invention.

When a therapeutically effective amount of a compound of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stabil-

- 29 -

ity, and the like, is within the skill in the art. A preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound of the present invention, an isotonic vehicle.

For oral administration, the compounds can be formulated readily by combining a compound of formula (I) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the present compounds to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by adding a compound of formula (I) with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.

For administration by inhalation, compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

- 30 -

The compounds can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formula-
5 tory agents such as suspending, stabilizing, and/or dispersing agents.
10

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension. Option-
15 ally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions. Alternatively, a present composition can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
20
25

Compounds of the present invention also can be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases. In addition to the
30 formulations described previously, the compounds also can be formulated as a depot preparation. Such long-acting formulations can be administered by

- 31 -

implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Many of the compounds of the present invention can be provided as salts with pharmaceutically compatible counterions. Such pharmaceutically acceptable base addition salts are those salts that retain the biological effectiveness and properties of the free acids, and that are obtained by reaction with suitable inorganic or organic bases.

In particular, a compound of formula (I) can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents. A compound also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.

For veterinary use, a compound of formula (I) or a nontoxic salt thereof, is administered as a

- 32 -


suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal.

Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (I), together with a pharmaceutically acceptable diluent or carrier therefor. There is further provided by the present invention a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I), together with a pharmaceutically acceptable diluent or carrier therefor.

In a particular embodiment, the invention includes a pharmaceutical composition for the curative or prophylactic treatment of erectile dysfunction in a male animal, or arousal disorder in a female animal, including humans, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.


Compounds of formula (I) can be prepared by any suitable method known in the art, or by the following processes which form part of the present invention. In the methods below, R^0 , R^1 , R^2 , R^3 , and R^4 are as defined in structural formula (I) above. In particular, Daugan U.S. Patent No. 5,859,006, incorporated herein by reference, discloses preparation of a compound of structural formula (III).

- 33 -




(III)

In short, the compound of structural formula (III),
i.e., the *cis*-isomer of Intermediates 1 and 2 of
Daugan U.S. Patent No. 5,859,006 was prepared ac-
cording to the following reaction scheme:





D-Tryptophan methyl ester




Piperonal

- 34 -



(42%)
(III) (cis-isomer)



(28%)
(IIIa) (trans-isomer).

A compound of structural formula (I) is prepared similarly by reacting a tryptophan ester, or a tryptophan ester substituted with suitable R^0

- 35 -

substituents, with a suitable aldehyde to provide the desired R¹ substituent. The resulting product then is hydrolyzed to the carboxylic acid, and cyclized by reaction with a suitable cyclizing agent like phosgene, thiocarbonyl diimidazole, or thio-phosgene, for example, to provide a compound of structural formula (I).

In the synthesis of compounds of structural formula (I), protecting compounds and protecting groups, like benzyl chloroformate and trichloroethyl chloroformate, which are well known to persons skilled in the art, can be used. Such protecting groups are disclosed, for example, in T.W. Greene et al. "Protective Groups in Organic Synthesis, Third Edition," John Wiley and Sons, Inc., NY, NY (1999). The structure of a compound of structural formula (I) can be varied by using an appropriate aldehyde to change the identity of R¹, or by using a halo or alkyl phenyl-substituted tryptophan ester.

Compounds of formula (I) can be converted to other compounds of formula (I). Thus, for example, when a compound contains a substituted aromatic ring, it is possible to prepare another suitably substituted compound of formula (I). Examples of appropriate interconversions include, but are not limited to, OR^b to hydroxy by suitable means (e.g., using an agent such as SnCl₂ or a palladium catalyst, such as palladium-on-carbon, or amino to substituted amino, such as alkylamine, using standard acylating or sulfonylating conditions.

Compounds of formula (I) can be prepared by the method above as individual stereoisomers from the appropriate stereoisomer of formula (III) or as

- 36 -

a racemic mixture from the appropriate racemic compound of formula (III). Individual stereoisomers of the compounds of the invention can be prepared from racemates by resolution using methods known in the art for the separation of racemic mixtures into their constituent stereoisomers, for example, using HPLC on a chiral column, such as Hypersil naphthyl urea, or using separation of salts of stereoisomers. Compounds of the invention can be isolated in association with solvent molecules by crystallization from, or evaporation of, an appropriate solvent.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) that contain a basic center can be prepared in a conventional manner. For example, a solution of the free base can be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt can be formed or interconverted using ion-exchange resin techniques. Thus, according to a further aspect of the invention, a method for preparing a compound of formula (I) or a salt or solvate (e.g., hydrate) is provided, followed by (i) salt formation, or (ii) solvate (e.g., hydrate) formation.

The following abbreviations are used hereafter in the accompanying examples: rt (room temperature), min (minute), h (hour), g (gram), mmol (millimole), m.p. (melting point), eq (equivalents),


- 37 -

L (liter), mL (milliliter), μ L (microliters), DMSO (dimethyl sulfoxide), CH_2Cl_2 (dichloromethane), MeOH (methanol), Et_3N (triethylamine), EtOAc (ethyl acetate), AcOH (acetic acid), HCl (hydrochloric acid), H_2S (hydrogen sulfide), aq (aqueous), NaOH (sodium hydroxide), t-Bu (tertiary butyl), NaCl (sodium chloride), MgSO_4 (magnesium sulfate), and THF (tetrahydrofuran).

The following illustrates specific examples of compounds of structural formula (I) and synthetic routes to some of these structures.


Preparation of Example 1

(3aR,10R) - (+) -10-Benzo[1,3]dioxol-5-yl-3a,4,9,10-tetrahydro-2-oxa-9,10a-diaza-cyclopenta[β]fluorene-1,3-dione



Example 1 can be prepared using the following synthetic sequence.


- 38 -




The addition of phosgene (COCl_2) to homoproline is described in S.H. Reich et al., *J. Med. Chem.*, 39, pp. 2781-2794 (1996).

Example 1 was prepared by the following alternative method. A suspension of Intermediate 1 (1.0 g, 3.0 mmol), Et_3N (1.0 mL, 7.1 mmol, 2.5 eq) and THF (25 mL) was immersed in a sonicator until all solid particles dissolved. Triphosgene (800 mg, 2.7 mmol) was added and the resulting suspension was stirred for 18 hours. A colorless solid was removed by filtration. The filtrate was concentrated and the crude residue was purified by chromatography (silica gel, 30% ethyl acetate: 70% hexanes) to provide 602 mg (55%) of Example 1 as a solid. mp 197-202°C. ^1H NMR ($\text{DMSO}-d_6$) δ : 10.7 (s, 1H), 7.55-6.35 (m, 7H), 6.0 (d, $J=15$ Hz, 2H), 5.8 (s, 1H), 4.9 (dd, $J=5.11$ Hz, 1H), 3.3 (m, 2H); MS FD m/e 362 (p).

- 39 -





Preparation of Example 2

Example 2 was prepared using the following synthetic sequence.



Intermediate 2


- 40 -




- 41 -

Preparation of Example 3

(3aR,10R)-10-Benzo[1,3]dioxol-5-yl-1-thioxo-3a,4,9,10-tetrahydro-2-oxa-9,10a-diazacyclopenta[β]fluoren-3-one



Example 3 was prepared by the following synthetic schemes.




Triethylamine (0.39 mL, 2.98 mmol) was added to a stirred mixture of Intermediate 1 (1 g, 2.7 mmol) and thiocarbonyl diimidazole (0.57 g, 3.2 mmol) in CH_2Cl_2 (15 mL) at room temperature. The resulting slurry was stirred for 18 hours at room temperature. The resulting solution was concen-

- 42 -



trated *in vacuo*. Chromatography (silica gel, hexanes to 6:4 methylene chloride:hexanes) of the residue provided 0.33 g (32%) of Example 3 as a cream solid: 129-132°C. ¹H NMR (DMSO-d₆) δ: 10.9 (s, 1H), 7.55 (d, J=7.68 Hz, 1H), 7.30 (d, J=7.68 Hz, 1H), 7.01-7.14 (m, 2H), 6.8-6.9 (m, 2H), 6.49 (s, 1H), 6.01 (s, 1H), 5.10 (dd, J=5.12, 10.98 Hz, 1H), 3.42 (dd, J=5.12, 15 Hz, 1H), 3.32 (s, 3H), 3.10 (dd, J=1.46, 15.00 Hz, 1H), 2.48-2.52 (m, 1H); IR (CHCl₃, cm⁻¹): 1735, 1691; MS FD m/e 378 (m+).

Example 3 also can be prepared by the following synthetic sequence:



Preparation of Example 4

Example 4 is prepared from Example 1 by the following reaction.




- 43 -

A general review of Lawesson's reagent can be found in M.P. Cava et al., *Tetrahedron*, 41, pp. 5061-5087 (1985).


5 Preparation of Example 5

(3aS,10R)-10-Benzo(1,3)dioxol-5-yl-2-methyl-
3-thioxo-2,3,3a,4,9,10-hexahydro-2,9,10a-
triazacyclopenta[b]fluoren-1-one




Example 5 is prepared from Intermediate 5 via a reaction with Lawesson's reagent. The synthesis of Intermediate 5 can be found in Daugan et al. U.S. Patent No. 6,001,847.


- 44 -



Intermediate 5



Lawesson's reagent



Example 5

Lawesson's reagent (0.43 g, 1.07 mmol) was added to a slurry of Intermediate 5 (0.40 g, 1.07 mmol) in anhydrous THF (25 mL). The mixture was stirred under a nitrogen blanket for 8 days at room temperature. LC/MS showed two peaks corresponding to Example 5, but only in 5-10% yield. The reaction


- 45 -

mixture was concentrated *in vacuo* and was taken up in toluene. An additional 80 mg of Lawesson's reagent was added and the slurry was warmed to 80°C for 4 hours. The reaction was cooled to room temperature, diluted with EtOAc (50 mL), and washed with saturated NaCl solution (20 mL). The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The product was purified by column chromatography (silica gel, 0-5% EtOAc/CH₂Cl₂) to provide an orange foam. Suspending the foam in MeOH and adding water gave a pale orange solid (112 mg, 26%) that was collected by filtration and dried *in vacuo* at 45°C: mp 168-174°C; TLC R_f (100% CH₂Cl₂)=0.60; ¹H NMR (300 MHz, DMSO-d₆): δ 10.87 (s, 1H), 7.55 (d, J=7.6 Hz, 1H), 7.30 (d, J=7.9 Hz, 1H), 7.10 (td, J=7.4 Hz, J=1 Hz, 1H), 7.02 (td, J=7 Hz, J=0.9 Hz, 1H), 6.92-6.86 (m, J=7.3 Hz, 1H), 6.17 (s, 1H), 6.00 (s, 2H), 4.90 (dd, J=5.5 Hz, J=10.6 Hz, 1H), 3.56 (dd, J=5.5 Hz, J=15.0 Hz, 1H), 3.21 (s, 3H), 2.76 (ddd, J=1.1 Hz, J=10.8 Hz, J=14.5 Hz, 1H); ¹³C NMR (300 MHz, DMSO-d₆): δ 202.6, 153.7, 147.2, 136.8, 133.5, 131.2, 125.7, 121.7, 118.2, 111.4, 108.2, 106.5, 101.2, 62.3, 52.8, 28.8, 26.6. MS (API) m/z 390 (M-H); [α]_D^{25°C}=-190.3° (c=0.21, DMSO). Anal. Calcd for C₂₁H₁₇N₃O₃S•0.35 H₂O: C, 63.41; H, 4.49; N, 10.56; S, 8.06. Found: C, 63.44; H, 4.28; N, 10.48; S, 8.37. The relative stereochemistry of Example 5 was confirmed to be the *trans* isomer by NOE difference experiments (DMSO-d₆): no NOE enhancements from the C12a proton at 4.90 ppm to the C6 proton at 6.17 ppm and a positive enhancement with a C12 proton at 3.56 ppm.

- 46 -

Preparation of Example 6

(3aS,10R)-10-Benzo(1,3)dioxol-5-yl-2-methyl-1-thioxo-1,2,3a,4,9,10-hexahydro-2,9,10a-triazacyclopenta[b]fluoren-3-one




A mixture of Intermediate IIIa (4.00 g, 10.34 mmol) and 150 mL of THF was cooled to 0°C, then triethylamine (2.2 mL) was added giving a clear solution, momentarily followed by a new white precipitate. The solid was filtered, then washed with THF (2 x 20 mL). The filtrate was concentrated in vacuo to yield a white foam. The foam was taken up in methyl ethyl ketone (50 mL), then methyl thioisocyanate (0.94 g, 12.92 mmol) was added. The mixture was warmed to reflux for 5 hours. The reaction mixture was cooled to room temperature and the mixture was concentrated in vacuo. Purification by flash chromatography on silica gel (0-3% EtOAc/-CH₂Cl₂) and trituration with diethyl ether (2 x 10 mL) provided the product as a bright yellow solid (3.05 g, 75%): mp 234-236°C; TLC R_f (5% EtOAc/-CH₂Cl₂)=0.68; ¹H NMR (300 MHz, DMSO-d₆): δ 10.97 (s, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.30 (d, J=7.0 Hz, 1H),

- 47 -

7.10 (dt, $J=7.3$ Hz, $J=0.9$ Hz, 1H), 6.89-7.05 (m, 4H), 6.77 (s, 1H), 6.00 (d, $J=1.2$ Hz, 2H), 4.87 (dd, $J=6.0$ Hz, $J=10.8$ Hz, 1H), 3.43 (dd, $J=6.1$ Hz, $J=15.1$ Hz, 1H), 3.14 (s, 3H), 2.88-2.97 (m, 1H); MS (API) m/z 390 (M-H); $[\alpha]_D^{25^\circ} = -410.25^\circ$ ($c=0.77$, DMSO).

Anal. Calcd for $C_{21}H_{17}N_3O_3S$: C, 64.43; H, 4.38; N, 10.73; S, 8.19. Found: C, 64.52; H, 4.49; N, 10.54; S, 8.36. The relative stereochemistry of Example 6 was confirmed to be the *trans* isomer by NOE difference experiments (DMSO- D_6): no NOE enhancements from the C3a proton at 4.87 ppm to the C10 proton at 6.77 ppm and a positive enhancement with benzene protons at 6.89-7.05 ppm.

Preparation of Example 6a



Example 6a was prepared in a manner identical to Example 6 using the appropriate stereoisomer of β -carboline hydrochloride, i.e., Intermediate III.



- 48 -

Examples 7-16

Examples 7-16 were prepared in a manner similar to Examples 1-6a.

Example 7

(+-, trans)-2-Butyl-10-(4-methoxyphenyl)-1-thioxo-1,2,3a,4,9,10-hexahydro-2,9,10a-triazacyclopenta-[b]fluoren-3-one

Example 8


- 49 -

Example 95-Benzo[1,3]dioxol-5-yl-5,6,11,11a-tetrahydro-
indolizino[6,7-b]indole-1,3-dione

5

10

15




20

Example 10

25

30


35




- 50 -

Example 11

(+-, cis)-10-Benzo[1,3]dioxol-5-yl-2-methyl-
2,3,3a,4,9,10-hexahydro-2,9,10a-triazacyclopenta-
[b]fluoren-1-one

Example 12


(+-, cis)-2-Benzyl-10-(4-methoxyphenyl)-
1,2,3a,4,9,10-hexahydro-2,9,10a-triazacyclopenta-
[b]fluoren-3-one




- 51 -

Example 13

10-Benzo[1,3]dioxol-5-yl-3a,4,9,10-tetrahydro-3H-2-
oxa-9,10a-diazacyclopenta[b]fluoren-1-one

Example 14



(+-, trans)-5-Benzo[1,3]dioxol-5-yl,2,3,5,6,11,11a-
hexahydro-indolizino[6,7-b]indol-1-one



- 52 -

Example 15

10-Benzo[1,3]dioxol-5-yl-3a,4,9,10-tetrahydro-3H-2-oxa-1-thia-9,10a-diazacyclopenta[b]fluorene-1-oxide

Example 16

Compounds of the present invention can be formulated into tablets for oral administration. For example, a compound of formula (I) can be formed into a dispersion with a polymeric carrier by the coprecipitation method set forth in WO 96/38131, incorporated herein by reference. The coprecipitated dispersion then can be blended with excipients, then pressed into tablets, which optionally are film-coated.

- 53 -

The compounds of structural formula (I) were tested for an ability to inhibit PDE5. The ability of a compound to inhibit PDE5 activity is related to the IC_{50} value for the compound, i.e., the concentration of inhibitor required for 50% inhibition of enzyme activity. The IC_{50} value for compounds of structural formula (I) were determined using recombinant human PDE5.

The compounds of the present invention typically exhibit an IC_{50} value against recombinant human PDE5 of less than about 50 μM , and preferably less than about 25 μM , and more preferably less than about 15 μM . The compounds of the present invention typically exhibit an IC_{50} value against recombinant human PDE5 of less than about 1 μM , and often less than about 0.05 μM . To achieve the full advantage of the present invention, a present PDE5 inhibitor has an IC_{50} of about 0.1 nM to about 15 μM .

The production of recombinant human PDEs and the IC_{50} determinations can be accomplished by well-known methods in the art. Exemplary methods are described as follows:

EXPRESSION OF HUMAN PDEs

Expression in *Saccharomyces cerevisiae* (Yeast)

Recombinant production of human PDE1B, PDE2, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, and PDE7 was carried out similarly to that described in Example 7 of U.S. Patent No. 5,702,936, incorporated herein by reference, except that the yeast transformation vector employed, which is derived from the basic

- 54 -

ADH2 plasmid described in Price et al., *Methods in Enzymology*, 185, pp. 308-318 (1990), incorporated yeast ADH2 promoter and terminator sequences and the *Saccharomyces cerevisiae* host was the protease-deficient strain BJ2-54 deposited on August 31, 1998 with the American Type Culture Collection, Manassas, Virginia, under accession number ATCC 74465. Transformed host cells were grown in 2X SC-leu medium, pH 6.2, with trace metals, and vitamins. After 24 hours, YEP medium-containing glycerol was added to a final concentration of 2X YET/3% glycerol. Approximately 24 hr later, cells were harvested, washed, and stored at -70°C.

HUMAN PHOSPHODIESTERASE PREPARATIONS

Phosphodiesterase Activity Determinations

Phosphodiesterase activity of the preparations was determined as follows. PDE assays utilizing a charcoal separation technique were performed essentially as described in Loughney et al. (1996). In this assay, PDE activity converts [32P]cAMP or [32P]cGMP to the corresponding [32P]5'-AMP or [32P]5'-GMP in proportion to the amount of PDE activity present. The [32P]5'-AMP or [32P]5'-GMP then was quantitatively converted to free [32P]phosphate and unlabeled adenosine or guanosine by the action of snake venom 5'-nucleotidase. Hence, the amount of [32P]phosphate liberated is proportional to enzyme activity. The assay was performed at 30°C in a 100 μ L reaction mixture containing (final concentrations) 40 mM Tris HCl (pH 8.0), 1 μ M ZnSO₄, 5 mM

- 55 -

MgCl₂, and 0.1 mg/mL bovine serum albumin (BSA). PDE enzyme was present in quantities that yield <30% total hydrolysis of substrate (linear assay conditions). The assay was initiated by addition of substrate (1 mM [32P]cAMP or cGMP), and the mixture was incubated for 12 minutes. Seventy-five (75) µg of *Crotalus atrox* venom then was added, and the incubation was continued for 3 minutes (15 minutes total). The reaction was stopped by addition of 200 µL of activated charcoal (25 mg/mL suspension in 0.1 M NaH₂PO₄, pH 4). After centrifugation (750 X g for 3 minutes) to sediment the charcoal, a sample of the supernatant was taken for radioactivity determination in a scintillation counter and the PDE activity was calculated.

Purification of PDE5 from *S. cerevisiae*

Cell pellets (29 g) were thawed on ice with an equal volume of Lysis Buffer (25 mM Tris HCl, pH 8, 5 mM MgCl₂, 0.25 mM DTT, 1 mM benzamidine, and 10 µM ZnSO₄). Cells were lysed in a Microfluidizer[®] (Microfluidics Corp.) using nitrogen at 20,000 psi. The lysate was centrifuged and filtered through 0.45 µm disposable filters. The filtrate was applied to a 150 mL column of Q SEPHAROSE[®] Fast-Flow (Pharmacia). The column was washed with 1.5 volumes of Buffer A (20 mM Bis-Tris Propane, pH 6.8, 1 mM MgCl₂, 0.25 mM DTT, 10 µM ZnSO₄) and eluted with a step gradient of 125 mM NaCl in Buffer A followed by a linear gradient of 125-1000 mM NaCl in Buffer A. Active fractions from the linear gradient were applied to a 180 mL hydroxyapatite column in Buffer

- 56 -

B (20 mM Bis-Tris Propane (pH 6.8), 1 mM MgCl_2 , 0.25 mM DTT, 10 μM ZnSO_4 , and 250 mM KCl). After loading, the column was washed with 2 volumes of Buffer B and eluted with a linear gradient of 0-125 mM potassium phosphate in Buffer B. Active fractions were pooled, precipitated with 60% ammonium sulfate, and resuspended in Buffer C (20 mM Bis-Tris Propane, pH 6.8, 125 mM NaCl, 0.5 mM DTT, and 10 μM ZnSO_4). The pool was applied to a 140 mL column of SEPHACRYL[®] S-300 HR and eluted with Buffer C. Active fractions were diluted to 50% glycerol and stored at -20°C .

The resultant preparations were about 85% pure by SDS-PAGE. These preparations had specific activities of about 3 μmol cGMP hydrolyzed per minute per milligram protein.

Inhibitory Effect on cGMP-PDE

cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells et al., *Biochim. Biophys. Acta*, 384, 430 (1975). The reaction medium contained 50 mM Tris-HCl, pH 7.5, 5 mM magnesium acetate, 250 $\mu\text{g/ml}$ 5'-Nucleotidase, 1 mM EGTA, and 0.15 μM 8-[H^3]-cGMP. Unless otherwise indicated, the enzyme used was a human recombinant PDE5 (ICOS Corp., Bothell, Washington).

Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

- 57 -

The IC₅₀ values for the compounds examined were determined from concentration-response curves typically using concentrations ranging from 10 nM to 10 μ M. Tests against other PDE enzymes using standard methodology showed that compounds of the invention are selective for the cGMP-specific PDE enzyme.

Biological Data

The compounds according to the present invention were typically found to exhibit an IC₅₀ value of less than 500 nM. An *in vitro* test data for representative compounds of the invention is given in the following table:

Table 1. <i>In vitro</i> results	
Example	PDE5 IC ₅₀ (nM)
1	205
3	53
5	12
6	12
7	20
9	200
11	60
12	60
13	70
14	390
15	20


- 58 -

Obviously, many modifications and variations of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof, and, therefore, only such limitations
5 should be imposed as are indicated by the appended claims.

- 59 -

WHAT IS CLAIMED IS:


1. A compound having a formula






wherein R^0 , independently, is selected from the group consisting of halo, C_{1-6} alkyl, aryl, heteroaryl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{3-8} cycloalkylQ, $C(=O)R^b$, $OC(=O)R^b$, $C(=O)OR^b$, C_{1-4} alkylene NR^bR^c , C_{1-4} alkyleneHet, C_{1-4} alkylene $C(=O)OR^b$, $C(=O)NR^bSO_2R^d$, $C(=O)C_{1-4}$ alkyleneHet, $C(=O)NR^bR^c$, $C(=O)NR^bR^d$, $C(=O)NR^bC_{1-4}$ alkylene OR^c , $C(=O)NR^bC_{1-4}$ alkyleneHet, OR^b , OC_{1-4} alkylene $C(=O)OR^b$, OC_{1-4} alkylene NR^bR^c , OC_{1-4} alkyleneHet, OC_{1-4} alkylene OR^b , OC_{1-4} alkylene $NR^bC(=O)OR^c$, NR^bR^c , NR^bC_{1-4} alkylene NR^bR^c , $NR^bC(=O)R^c$, $NR^bC(=O)NR^bR^c$, $N(SO_2C_{1-4}alkyl)_2$, $NR^b(SO_2C_{1-4}alkyl)$, nitro, trifluoromethyl, trifluoromethoxy, cyano, $SO_2NR^bR^c$, SO_2R^b , SOR^b , SR^b , and OSO_2CF_3 ;

R^1 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, an optionally substituted C_{3-8} cycloalkyl ring, an optionally substituted C_{3-8} heterocycloalkyl ring, an optionally substituted bicyclic ring

- 60 -




wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one to three heteroatoms selected from oxygen, sulfur, and nitrogen, hydrogen, C_{1-6} alkyl, aryl C_{1-3} alkyl, C_{1-3} alkenyl-aryl, halo C_{1-6} alkyl, C_{1-4} alkyleneC(=O)OR^b, C_{1-4} alkyleneC(=O)NR^bR^c, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, C_{3-8} heterocycloalkenyl, C_{1-4} alkyleneHet, C_{1-4} alkyleneQR^b, C_{2-6} -alkenyleneQR^b, C_{1-4} alkyleneQC C_{1-4} alkyleneQR^b,



and a spiro substituent having the structure

- 61 -



R² and R⁴, independently, are selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, heteroaryl, arylC₁₋₃alkyl, C₁₋₃alkylenearyl, C₁₋₃alkyleneHet, C₃₋₈cycloalkyl, and C₃₋₈heterocycloalkyl;

R³ is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, C₂₋₆alkenyl, C₁₋₃alkylenearyl, arylC₁₋₃alkyl, C(=O)R^b, aryl, heteroaryl, C(=O)R^b, C(=O)NR^bR^c, C(=O)NR^bR^d, C(=S)NR^bR^c, C(=S)NR^bR^d, SO₂R^b, SO₂NR^bR^c, S(=O)R^b, S(=O)NR^bR^c, C(=O)NR^bC₁₋₄alkyleneOR^b, C(=O)-NR^bC₁₋₄alkyleneHet, C(=O)C₁₋₄alkylenearyl, C(=O)-C₁₋₄alkyleneheteroaryl, C₁₋₄alkylenearyl substituted with one or more of SO₂NR^bR^c, NR^bR^c, C(=O)OR^b, NR^bSO₂CF₃, CN, NO₂, C(=O)R^b, OR^b, C₁₋₄alkyleneNR^bR^c, and OC₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneHet, C₁₋₄alkyleneC(=O)C₁₋₄alkylenearyl, C₁₋₄alkyleneC(=O)C₁₋₄alkyleneheteroaryl, C₁₋₄alkyleneC(=O)Het, C₁₋₄alkyleneC(=O)NR^bR^c, C₁₋₄alkyleneOR^b, C₁₋₄alkyleneNR^bC(=O)R^b, C₁₋₄alkyleneOC₁₋₄alkyleneOR^b, C₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneC(=O)OR^b, and C₁₋₄alkyleneOC₁₋₄alkyleneC(=O)OR^b;

X and Y, independently, are selected from the group consisting of C(=O), SO, SO₂, C(=S), C(R^a)₂, and C=C(R^a)₂;

Z is O, X, or C(R^a)₂, or Z is NR^d when X or Y is SO, SO₂, C(=S), C(R^a)₂ or C=C(R^a)₂;

- 62 -

R^a , independently, is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, aryl, heteroaryl, aryl C_{1-3} alkyl, C_{1-3} -alkylenearyl, $C(=O)OR^b$, $C(=O)NR^bR^d$, C_{1-4} alkylene NR^bR^c , halo, NO_2 , CF_3 , CF_3O , OR^b , $OC(=O)R^b$, OC_{1-4} alkylene- $C(=O)OR^b$, C_{1-4} alkylene OC_{1-4} alkylene $C(=O)OR^b$, $C(=O)-NR^bSO_2R^d$, $C(=O)C_{1-4}$ alkyleneHet, C_{2-6} alkenylene NR^bR^c , $C(=O)NR^aC_{1-4}$ alkylene OR^c , $C(=O)NR^bC_{1-4}$ alkyleneHet, OC_{2-4} -alkylene NR^bR^c , OC_{1-4} alkylene $CH(OR^b)CH_2NR^bR^c$, OC_{2-4} alkylene OR^b , OC_{2-4} alkylene $NR^bC(=O)OR^c$, NR^bR^c , NR^bC_{1-4} alkylene- NR^bR^c , $NR^bC(=O)R^c$, $NR^bC(=O)NR^bR^c$, $N(SO_2C_{1-4}alkyl)_2$, $NR^b-(SO_2C_{1-4}alkyl)$, $SO_2NR^bR^c$, OSO_2 trifluoromethyl, $C(=O)R^b$, C_{1-3} alkylene OR^b , CN, and C_{1-6} alkylene $C(=O)OR^b$;

R^b is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylene-aryl, heteroaryl, heteroaryl C_{1-3} alkyl, and C_{1-3} alkyleneheteroaryl;

R^c is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-3} alkylene $N(R^b)_2$, aryl, aryl C_{1-3} alkyl, C_{1-3} alkylenearyl, and heteroaryl;

R^d is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl, aryl C_{1-3} alkyl, heteroaryl C_{1-3} alkyl, C_{1-3} alkylene $N(R^a)_2$, C_{1-6} alkylene-aryl, C_{1-6} alkyleneHet, halo C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, C_{1-3} alkyleneHet, C_{1-3} alkyleneheteroaryl, C_{1-6} alkylene $C(=O)OR^a$, and C_{1-3} alkylene C_{3-8} -heterocycloalkyl;

or R^b and R^d are taken together to form a 5- or 6-membered ring, optionally containing at least one heteroatom;

R^e is null or is selected from the group consisting of hydrogen, C_{1-6} alkyl, aryl, heteroaryl,

- 63 -

arylC₁₋₃alkyl, heteroarylC₁₋₃alkyl, C₁₋₃alkylenearyl,
and C₁₋₃alkyleneheteroaryl;

Q is O, S, or NR^b;

B is O, S, or NR^e;

C is O, S, or NR^b;

D is CR^b or N;


E is CR^b, C(R^a)₂, or NR^e;

Het represents a 5- or 6-membered hetero-
cyclic ring, saturated or partially or fully unsatu-
rated, containing at least one heteroatom selected
from the group consisting of oxygen, nitrogen, and
sulfur, and optionally substituted with C₁₋₄alkyl or
C(=O)OR^b;

q is 0, 1, 2, 3, or 4; and

pharmaceutically acceptable salts and
hydrates thereof.

2. The compound of claim 1 represented
by the formula



and pharmaceutically acceptable salts and
solvates thereof.

3. The compound of claim 1 wherein q is
0.





- 64 -

4. The compound of claim 1 wherein R^0 is selected from the group consisting of aryl, Het, OR^a , $C(=O)OR^a$, $C_{1-4}alkyleneNR^aR^b$, $OC(=O)R^a$, $C(=O)R^a$, NR^aR^b , $C_{3-7}cycloalkyl$, $C_{3-7}cycloalkylQ$, $C(=O)NR^aR^b$, and $C(=O)NR^aR^c$, or two R^0 groups are taken together with the carbon atoms to which they are attached to form a 5- or 6-membered ring, saturated or partially or fully saturated, optionally substituted and optionally containing one or two heteroatoms selected from oxygen, nitrogen, and sulfur.


5. The compound of claim 1 wherein R^1 is selected from the group consisting of hydrogen, $C_{1-4}alkyl$, $haloC_{1-4}alkyl$, optionally substituted benzyl, $C_{3-6}cycloalkylmethyl$, $pyridylC_{1-3}alkyl$, and $furyl-C_{1-3}alkyl$.

- 65 -

6. The compound of claim 1 wherein R^1 is selected from the group consisting of C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{3-6} cycloalkenyl, C_{1-4} alkylene QR^a , C_{2-4} alkenylene QR^a , C_{1-4} alkylene QC_{1-4} -alkylene QR^a ,



and








- 66 -

wherein q is an integer 1 or 2, and G , independently, is $C(R^a)_2$, O , S , or NR^a .






- 67 -

7. The compound of claim 1 wherein R^2 is selected from the group consisting of




$-CH_2OR^a$, $-CH_2OCH_2OR^a$,

- 68 -



and

- 69 -





each optionally substituted with halogen, C₁₋₃alkyl, OR^a, CO₂R^a, halomethyl, halomethoxy, cyano, nitro, and NR^aR^b.

8. The compound of claim 7 wherein R^a is selected from the group consisting of hydrogen, C₁₋₆alkyl, and benzyl.

9. The compound of claim 1 wherein R² and R⁴, independently, are selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, and heteroaryl.

- 70 -







10. The compound of claim 1 wherein R³ is selected from the group consisting of benzimidazole, a triazole, imidazole, C₁₋₄alkyleneHet, wherein Het is selected from the group consisting of piperazine, morpholine, pyrrolidine, pyrrolidone, tetrahydrofuran, piperidine,










C₁₋₄alkyleneC₆H₅, optionally substituted with one to three groups selected from the group consisting of C(=O)OR^b, NR^bR^c, NR^bSO₂CF₃, SO₂NR^bR^c, CN, OR^b, C(=O)R^b, C₁₋₄alkyleneNR^bR^c, nitro, OC₁₋₄alkylenearyl, and OC₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneC(=O)benzyl, C₁₋₄alkyleneC(=O)OR^b, C₁₋₄alkyleneC(=O)NR^bR^c, C₁₋₄alkyleneC(=O)NR^bR^d, C₁₋₄alkyleneHet, NR^bR^c, OH, OC₁₋₄alkyl, C₆H₅, C₁₋₄alkyleneNR^bR^c, C₁₋₄alkyleneOR^b, C₁₋₄alkyleneNHC(=O)R^b, and C₁₋₄alkyleneOC₁₋₄alkyleneOR^b.

- 71 -




11. The compound of claim 1 wherein
-X-Y-Z- is selected from the group consisting of



- 72 -







- 73 -






wherein R^d is hydrogen, benzyl, or C₁₋₆alkyl.

- 74 -


12. The compound of claim 1 wherein R^1 is selected from the group consisting of



- 75 -








and









R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, $\text{C}(=\text{O})\text{NR}^b\text{R}^d$, and C_{1-4} alkyleneHet; R^2 and R^4 are selected from the group consisting of hydrogen

- 76 -






and C₁₋₆alkyl; and -X-Z-Y- is selected from the group consisting of



- 77 -





- 78 -






wherein R^d is hydrogen, benzyl, or C₁₋₆alkyl.

- 79 -




13. A compound selected from the group consisting of






- 80 -






- 81 -





- 82 -




- 83 -



- 84 -



- 85 -



and pharmaceutically acceptable salts and solvates thereof.

14. A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

15. A method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.

16. The method of claim 15 wherein the condition is male erectile dysfunction.

17. The method of claim 16 wherein the treatment is an oral treatment.

- 86 -

18. The method of claim 15 wherein the condition is female arousal disorder.

19. The method of claim 18 wherein the treatment is an oral treatment.

20. The method of claim 15 wherein the condition is selected from the group consisting of stable angina, unstable angina, variant angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, malignant hypertension, pheochromocytoma, acute respiratory distress syndrome, congestive heart failure, acute renal failure, chronic renal failure, atherosclerosis, a condition of reduced blood vessel patency, a peripheral vascular disease, a vascular disorder, thrombocythemia, an inflammatory disease, myocardial infarction, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, peptic ulcer, a gut motility disorder, postpercutaneous transluminal coronary angioplasty, carotid angioplasty, post-bypass surgery graft stenosis, osteoporosis, preterm labor, benign prostatic hypertrophy, and irritable bowel syndrome.

21. A method of treating a condition where inhibition of a cGMP-specific PDE is of therapeutic benefit, in a human or a nonhuman animal body, comprising administering to said body a therapeutically effective amount of a compound of claim 1.

- 87 -

22. A method for the curative or prophylactic treatment of male erectile dysfunction or female arousal disorder, comprising administration of an effective dose of a compound of claim 1, and pharmaceutically acceptable salts and solvates thereof, to an animal.

23. Use of a compound of claim 1 for the manufacture of a medicament for the curative or prophylactic treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/028865 A3

(51) International Patent Classification⁷: **C07D 498/14**,
A61K 31/437, A61P 9/00, 15/10, C07D 513/14, 471/14,
515/14 // (C07D 498/14, 263:00, 221:00, 209:00) (C07D
513/14, 277:00, 221:00, 209:00) (C07D 471/14, 235:00,
221:00, 209:00) (C07D 471/14, 221:00, 209:00, 209:00)
(C07D 515/14, 291:00, 221:00, 209:00)

Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis
(FR). **SCHULTZE, Lisa, M.** [US/US]; 16110 N.E. 175th
Street, Woodinville, WA 98072 (US).

(21) International Application Number: PCT/US01/42175

(22) International Filing Date:
17 September 2001 (17.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/237,734 3 October 2000 (03.10.2000) US

(71) Applicant (for all designated States except US): **LILLY
ICOS LLC** [US/US]; 1209 Orange Street, Wilmington, DE
19801 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ORME, Mark,
W.** [US/US]; 4235 Francis Avenue #203, Seattle, WA
98103 (US). **SAWYER, Jason, Scott** [US/US]; 5718
North Winthrop Avenue, Indianapolis, IN 46200 (US).
DAUGAN, Alain, Claude-Marie [FR/FR]; Centre de
Recherche Glaxo Smith Kline Courtaboeuf Z.A. de
Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis
(FR). **GOSIMINI, Romain, Luc, Marie** [FR/FR]; Centre
de Recherche Glaxo Smith Kline Courtaboeuf Z.A. de

(74) Agent: **NAPOLI, James, J.**; Marshall, Gerstein & Borun,
6300 Sears Tower, 233 South Wacker Drive, Chicago, IL
60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).


Published:

— with international search report

(88) Date of publication of the international search report:
27 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CONDENSED PYRIDOINDOLE DERIVATIVES



(I)

(57) Abstract: Compounds of general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents. In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3', 5' -monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/42175

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D498/14 A61K31/437 A61P9/00 A61P15/10 C07D513/14
C07D471/14 C07D515/14 //(C07D498/14,263:00,221:00,209:00),
(C07D513/14,277:00,221:00,209:00),(C07D471/14,235:00,221:00,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 357 122 A (DUPHAR INT RES) 7 March 1990 (1990-03-07) table B, compounds 22-25,27-38,41-60; claims 1,5 table B	1,14
X	--- DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TANABE SIYAKU: "Tetrahydro-.beta.-carboline derivatives" retrieved from STN Database accession no. 1986:608864 XP002204315 abstract and RNs '104800-83-1! '104818-83-1! '104818-15-7! & JP 61 063682 A (TANABE SIYAKU) 1 April 1986 (1986-04-01) --- -/--	1,14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

2 July 2002

Date of mailing of the international search report

21/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/42175

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 209:00), (C07D471/14, 221:00, 209:00, 209:00), (C07D515/14, 291:00, 221:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KUMAR, N. ET AL.: "Agents acting on CNS: Part XXXI-Synthesis of 2-substituted 1,2,3,5,11,11a-hexahydro-6H-imidazo '5,1:6,1! pyrido '3,4-b! indoles" INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL., vol. 19B, no. 12, 1980, pages 1087-1088, XP008004701 PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI., IN ISSN: 0019-5103 compounds 4,7,13 ---	1, 14
X	WO 94 10175, A (UNIV VIRGINIA ;US ARMY (US)) 11 May 1994 (1994-05-11) claim 1; pages 16-18, compounds 1-4; page 19, compound 8, page 20, compound 7; page 22-25 ,compounds 9,10,1c,6, 1d,1e,1f,11 --- -/--	1, 14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 July 2002

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I .

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MADALENGOITIA, J.S. ET AL.: "Structure-activity relationship for DNA topoisomerase II-induced DNA cleavage by azatoxin analogues" BIOORGANIC & MEDICINAL CHEMISTRY., vol. 5, no. 9, 1997, pages 1807-1815, XP002204309 ELSEVIER SCIENCE LTD., GB ISSN: 0968-0896 table 1 ---	1,14
X	LETEURTRE, F. ET AL.: "Azatoxin derivatives with potent and selective action on topoisomerase II" BIOCHEMICAL PHARMACOLOGY, vol. 49, no. 9, 1995, pages 1283-1290, XP002204310 PERGAMON, OXFORD, GB ISSN: 0006-2952 page 1284, compounds 1-4 ---	1,14
X	LOPEZ RODRIGUEZ M L ET AL: "REACTION OF 6-HYDROXYTETRAHYDRO-BETA-CARBOLINE-3-CARBO XYLIC ACIDS WITH ISOCYANATES AND ISOTHIOCYANATES" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 42, no. 10, 1 October 1994 (1994-10-01), pages 2108-2112, XP000608286 ISSN: 0009-2363 tables II,IV ---	1,14
X	BRAÑA M F ET AL: "SYNTHESIS AND REACTIVITY OF BETA-CARBOLINE-HYDANTOIN SYSTEMS" SYNTHETIC COMMUNICATIONS, MARCEL DEKKER, INC., BASEL, CH, vol. 20, no. 12, 1990, pages 1793-1810, XP000196528 ISSN: 0039-7911 pages 1805-06, 4m, 4n, 4o, 4p, 4q, 4r ---	1
X	DEL GIUFICE, M.R. ET AL.: "New tetracyclic compounds containing the beta-carboline moiety" JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 27, 1990, pages 967-973, XP002204311 HETEROCORPORATION. PROVO., US ISSN: 0022-152X page 971, compounds IXk-IXn,Xi,Xj --- -/--	1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAIGA, Y. ET AL.: "Synthesis of 1,2,3,4-tetrahydro-beta-carboline derivatives as hepatoprotective agents. III. Introduction of substituents onto methyl 1,2,3,4-tetrahydro-beta-carboline-2-carboxithioate" CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 35, no. 8, 1987, pages 3284-3291, XP002204312 PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP ISSN: 0009-2363 page 3289, compound 14 ----	1
X	HINO T ET AL: "RADIATION-PROTECTIVE AGENTS. IV. SYNTHESIS OF TETRAHYDRO-BETA-CARBOLINES AND 2-AMINOTHIAZOLINE DERIVATIVE FROM TRYPTOPHANOLS" CHEMICAL AND PHARMACEUTICAL BULLETIN, TOKYO, JP, vol. 2, no. 18, 1970, pages 384-388, XP008004700 ISSN: 0009-2363 compounds V and VIII ----	1
X	FALTZ ET A.: "Synthesis of optically active, condensed tetrahydropyridin-3-ones as precursors of alkaloid analogs" SYNLETT., no. 9, 1997, pages 1071-1072, XP002204313 THIEME VERLAG, STUTTGART., DE ISSN: 0936-5214 compound 4a ----	1
X	LOPEZ-RODRIGUEZ, M.L. ET AL.: "Stereospecificity in the reaction of tetrahydro-beta-carboline-3-carboxylic acids with isocyanates. Kinetic vs thermodynamic control" JOURNAL OF ORGANIC CHEMISTRY., vol. 59, no. 6, 1994, pages 1583-1585, XP002204314 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 compounds 2a-2f ----	1
A	WO 96 32003 A (GLAXO WELLCOME) 17 October 1996 (1996-10-17) claims 1,13 -----	1,15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/42175

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15 - 22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/42175

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0357122	A	07-03-1990	AU 625068 B2	02-07-1992
			AU 4083089 A	10-05-1990
			CA 1337200 A1	03-10-1995
			DK 417289 A	01-03-1990
			EP 0357122 A2	07-03-1990
			IL 91452 A	30-05-1994
			JP 2111772 A	24-04-1990
			NZ 230431 A	26-03-1992
			US 5095020 A	10-03-1992
			ZA 8906473 A	26-09-1990
JP 61063682	A	01-04-1986	NONE	
WO 9410175	A	11-05-1994	US 5622960 A	22-04-1997
			AT 169022 T	15-08-1998
			AU 676511 B2	13-03-1997
			AU 5325494 A	24-05-1994
			CA 2147608 A1	11-05-1994
			DE 69320052 D1	03-09-1998
			DE 69320052 T2	07-01-1999
			DK 665846 T3	03-05-1999
			EP 0665846 A1	09-08-1995
			WO 9410175 A1	11-05-1994
			US 5606060 A	25-02-1997
			US 5747520 A	05-05-1998
WO 9632003	A	17-10-1996	AT 211139 T	15-01-2002
			AU 702548 B2	25-02-1999
			AU 6613896 A	30-10-1996
			BR 9609503 A	08-03-2000
			CA 2226759 A1	17-10-1996
			CN 1195350 A	07-10-1998
			DE 69618231 D1	31-01-2002
			WO 9632003 A2	17-10-1996
			EP 0859778 A2	26-08-1998
			JP 11509517 T	24-08-1999
			US 6143757 A	07-11-2000
			US 6218400 B1	17-04-2001
			US 6001847 A	14-12-1999